文献速递牙周病

rhFGF-2联合DBBM或单用rhFGF-2牙周手术的2年随机对照随访

Periodontal surgery using rhFGF-2 with deproteinized bovine bone mineral or rhFGF-2 alone: 2-year follow-up of a randomized controlled trial.
PubMed 文献 · J Clin Periodontol · 2020-11-12

本研究为随机对照试验的2年随访,比较rhFGF-2联合脱蛋白牛骨矿物(DBBM)与单用rhFGF-2治疗骨内缺损的疗效。联合组影像学骨填充(RBF)显著优于单用组。

要点

  • 两组2年CAL均显著改善,联合组3.4±1.3 mm,单用组3.1±1.5 mm,组间无差异。
  • 联合组RBF达56%,单用组41%,联合治疗影像学骨填充更优。
  • 单用组在含壁缺损中CAL和RBF表现更佳,患者报告结局组间无差异。

核心结论

  • 2年随访时联合治疗与单用rhFGF-2在改善CAL上效果相似,但联合治疗获得显著更大的RBF。
  • 两种治疗均可维持临床、影像学和患者报告结局至少2年。

研究设计与样本

  • 随机对照试验的2年随访,缺损随机分配至rhFGF-2+DBBM(试验组)或单用rhFGF-2(对照组)。

主要发现

  • 两组CAL均较基线显著改善,试验组增益3.4±1.3 mm,对照组3.1±1.5 mm,组间无显著差异。
  • 两组RBF均渐进增加,试验组56%高于对照组41%。
  • 对照组在含壁缺损中CAL和RBF表现更好。
  • 患者报告结局组间无显著差异。

临床怎么用

  • 对于骨内缺损,两种方案均可获得至少2年的临床和影像学获益。
  • 若以影像学骨填充为主要目标,可考虑rhFGF-2联合DBBM。
  • 含壁缺损可能更适合单用rhFGF-2,但需结合具体缺损形态判断。

局限性

  • 含壁缺损的亚组结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To compare outcomes of rhFGF-2 + DBBM therapy with rhFGF-2 alone in the treatment of intrabony defects. This study provides 2-year follow-up results from the previous randomized controlled trial. MATERIALS AND METHODS: Defects were randomly allocated to receive rhFGF-2 + DBBM (test) or rhFGF-2 (control). Treated sites were re-evaluated at 2 years postoperatively, using original clinical and patient-centred measures. RESULTS: Thirty-eight sites were available for re-evaluation. At 2 years, both groups showed a significant improvement in clinical attachment level (CAL) from baseline. A gain in CAL of 3.4 ± 1.3 mm in the test group and 3.1 ± 1.5 mm in the control group was found. No significant inter-group difference was noted. Both groups showed a progressive increase in radiographic bone fill (RBF). The test treatment yielded greater RBF (56%) compared with the control group (41%). The control treatment performed better in contained defects in terms of CAL and RBF. There was no significant difference in patient-reported outcomes between groups. CONCLUSIONS: At 2-year follow-up, the test and cotrol treatments were similarly effective in improving CAL, whereas the test treatment achieved a significantly greater RBF. In both treatments, favourable clinical, radiographic, and patient-reported outcomes can be sustained for at least 2 years. TRIAL REGISTRATION: The University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) 000025257.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Aoki H, Bizenjima T, Seshima F, et al. Periodontal surgery using rhFGF-2 with deproteinized bovine bone mineral or rhFGF-2 alone: 2-year follow-up of a randomized controlled trial. J Clin Periodontol. 2020. PMID: 33030228. doi:10.1111/jcpe.13385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。